A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor and Diffuse Intrinsic Pontine Glioma (PBTC-036)

Trial Profile

A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor and Diffuse Intrinsic Pontine Glioma (PBTC-036)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Imetelstat (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; Ependymoma; Glioma; Gliosarcoma; Medulloblastoma; Oligodendroglioma; Primitive neuroectodermal tumours
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top